WP1122
Glioblastoma Multiforme
Key Facts
About Moleculin Biotech
Moleculin Biotech is a clinical-stage company focused on developing novel therapeutics for difficult-to-treat cancers and viruses, with a core mission to overcome the limitations of existing anthracyclines. Its key achievement is the advanced development of Annamycin, a next-generation, non-cardiotoxic anthracycline poised to enter a pivotal Phase 3 trial (MIRACLE) for relapsed/refractory AML. The company's strategy leverages a lean operational model and a multi-pronged pipeline to de-risk development and address significant unmet medical needs in oncology and virology.
View full company profileAbout Moleculin Biotech
Moleculin Biotech is a clinical-stage company focused on developing novel therapeutics for difficult-to-treat cancers and viruses, with a core mission to overcome the limitations of existing anthracyclines. Its key achievement is the advanced development of Annamycin, a next-generation, non-cardiotoxic anthracycline poised to enter a pivotal Phase 3 trial (MIRACLE) for relapsed/refractory AML. The company's strategy leverages a lean operational model and a multi-pronged pipeline to de-risk development and address significant unmet medical needs in oncology and virology.
View full company profileOther Glioblastoma Multiforme Drugs
| Drug | Company | Phase |
|---|---|---|
| Aldoxorubicin (LADR-7) | LadRx | Phase 2 |
| INV441 | invIOs | Pre-clinical |
| TLR-011 (Nabiximols) | Tilray | Phase 2 |
| certepetide (LSTA1) | Lisata Therapeutics | Phase 1/2 |